ImmunityBio, Inc. Common Stock Earnings Dividend

ImmunityBio, Inc. Common Stock’s revenue jumped 93.91% since last year same period to $51.24Mn in the Q2 2026. On a quarterly growth basis, ImmunityBio, Inc. Common Stock has generated 15.91% jump in its revenue since last 3-months.

ImmunityBio, Inc. Common Stock’s net profit fell -148.91% since last year same period to $-230.38Mn in the Q2 2026. On a quarterly growth basis, ImmunityBio, Inc. Common Stock has generated 63.59% jump in its net profits since last 3-months.

ImmunityBio, Inc. Common Stock’s net profit margin fell -28.37% since last year same period to -449.61% in the Q2 2026. On a quarterly growth basis, ImmunityBio, Inc. Common Stock has generated 68.59% jump in its net profit margins since last 3-months.

ImmunityBio, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at -0.09 - a -28.57% fall from last quarter’s estimates.

ImmunityBio, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at -0.09.

ImmunityBio, Inc. Common Stock’s earning per share (EPS) jumped 20% since last year same period to -0.08 in the Q2 2026. This indicates that the ImmunityBio, Inc. Common Stock has generated 20% annual rate of jump in its earning per share (EPS) in the last 4 quarters.